ADDED
As of February 23, 2026, there were 31,230,632 outstanding shares of the registrant s common stock.
and foreign laws and regulations applicable to our business, and our ability to comply with these regulations; our ability to effectively respond to the results of payor audits and government audits and investigations, such as our currently ongoing U.S.
Department of Health Resources and Services Administration, or HRSA, audit and Civil Investigative Demands, or CIDs; our ability to prevent errors in interpreting the results of our tests so as to avoid product liability and professional liability claims; our ability to obtain and maintain coverage and adequate reimbursement for our tests and to manage the complexity of billing and collecting such reimbursement; our beliefs that our tests marketed in the United States are, and will continue to be, laboratory developed tests; changes to the state of the U.S.
and foreign healthcare markets, including the role of governments in the healthcare industry, and the impact of general uncertainty in the U.S.
We have also made significant investment in digital pathology using artificial intelligence, or AI, technology, which allows us to digitize specimen slides instead of the traditional method of microscopy.
Additionally, we have developed our own image management system, which was created to address the growing demand for custom features necessitated by our high daily case throughput, to support all lines of business and to enable the deployment and integration of AI tools to assist pathologists in their diagnoses.
These platforms provide a broad test menu, the ability to rapidly develop and launch new tests, customizable test offerings, lower cost per test, and high efficiency.
A small percentage of our customers are patients who elect to pay for tests or testing services themselves, with out-of-pocket payments, after their physicians have ordered our tests or testing services.
Aggregating customers that are under common control, one of our customers contributed $70.8 million or 22% of our total revenue in 2025, and $62.6 million or 22% of our total revenue in 2024.
Laboratory Services Research and Development We have assembled a highly-qualified team with expertise in a number of fields important to our business, such as bioinformatics, genetics, software engineering, AI R D engineering, and laboratory management.
REMOVED
For purposes of this calculation, it has been assumed that all shares of the registrant s common stock held by directors, executive officers and persons beneficially owning 5% or more of the registrant s common stock are held by affiliates; however, the treatment of these persons as affiliates for purposes of this calculation is not, and shall not be considered, a determination as to whether such persons are affiliates of the registrant for any other purpose.
As of February 24, 2025 , there were 30,829,454 outstanding shares of the registrant s common stock.
and foreign laws and regulations applicable to our business, and our ability to comply with these regulations, and the results or potential liability associated with disclosure pursuant to any voluntary disclosure process by and between us and applicable regulatory agencies and bodies; our ability to effectively respond to the results of payor audits and government audits and investigations, such as our currently ongoing U.S.
Department of Health Resources and Services Administration, or HRSA, audit and Civil Investigative Demands, or CIDs; our ability to prevent errors in interpreting the results of our tests so as to avoid product liability and professional liability claims; our ability to obtain and maintain coverage and adequate reimbursement for our tests and to manage the complexity of billing and collecting such reimbursement; the state of the U.S.
and foreign healthcare markets, including the role of governments in the healthcare industry, generally, pressures or incentives to reduce healthcare costs while expanding individual benefits, and the impact of general uncertainty in the U.S.
This platform provides a broad test menu, the ability to rapidly develop and launch new tests, customizable test offerings, lower cost per test, and high efficiency.
As an example, this technology platform allowed us to rapidly respond to the 2019 novel coronavirus disease, or COVID-19, pandemic and scale our business to provide COVID-19 tests with reliable results and rapid turnaround time in a way that surpassed even our largest competitors.
We are proud that through this effort we supplied approximately 19.4 million COVID-19 tests from 2020 through 2023.
Ampullary market opportunity for 2 nd line therapy 2 Our current research and development progress for certain of our candidates and assets is shown in the pipeline chart below.
A small percentage of our customers are patients, who elect to pay for tests or testing services themselves with out-of-pocket payments after their physicians have ordered our tests or testing services.